Gene Mutations in Patients With Advanced Prostate Cancer That Is Not Responsive to Hormone Therapy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00002924|
Recruitment Status : Completed
First Posted : May 24, 2004
Last Update Posted : July 14, 2016
RATIONALE: Gene mutations may make prostate cancer cells unable to attach to androgens. This may permit the growth of prostate cancer. Gene testing may improve the identification of patients with advanced prostate cancer.
PURPOSE: Clinical trial to study the androgen receptor gene in patients with prostate cancer that is not responsive to hormone therapy.
|Condition or disease||Intervention/treatment|
|Prostate Cancer||Other: mutation analysis|
- the feasibility of collecting bone marrow biopsies from prostate cancer patients in a cooperative group setting
- the incidence of marrow invasion by prostate tumor in random bone marrow biopsy
- the influence of previous prostate radiation on obtaining prostate tumor
- the frequency and type of AR mutations and
- association of AR mutations with response to antiandrogen withdrawal.
|Study Type :||Observational|
|Actual Enrollment :||184 participants|
|Official Title:||Androgen Receptor Mutations in Hormone Refractory Prostate Cancer|
|Study Start Date :||January 1997|
|Actual Primary Completion Date :||June 2006|
|Actual Study Completion Date :||June 2006|
Source of patient samples
The CALGB conducted a phase III study (CALGB 9583) in which 260 men with AiPC were randomly assigned to antiandrogen withdrawal together with simultaneous ketoconazole and hydrocortisone versus antiandrogen withdrawal alone, followed by sequential ketoconazole and hydrocortisone. Metastatic disease with progression despite castrate levels of testosterone, prior antiandrogen therapy for a minimum of 4 weeks, and a minimum PSA level of 5 ng/mL were required; treatment with sequential antiandrogens was allowed. No prior chemotherapy was allowed. Bone marrow biopsies were obtained from 164 patients enrolled on CALGB 9583 and from 20 patients enrolled on CALGB chemotherapy trials (CALGB 9480, 9680, 9780).
|Other: mutation analysis|
- overall survival [ Time Frame: Up to 10 years ]
- response rate [ Time Frame: Up to 10 years ]
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00002924
Show 49 Study Locations
|Study Chair:||Mary-Ellen Taplin, MD||University of Massachusetts, Worcester|